Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro- and anti-inflammatory markers

Clinical Lipidology

Volumn 8, Issue 1, 2013, Pages 151-157

  Liu, Jun ^a   Luo, Song Hui ^a,b   Qing, Ping ^a   Di, Long Hui ^a   You, Xiang Dong ^a   Han, Hong Yan ^a   Jia, Yan Jun ^a   Li, Xiao Lin ^a   Wen, Dan ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

^b Fifth Hospital of Wuhan City   (China)

Author keywords

dyslipidemia; inflammation; pleiotropic effects; statin; Xuezhikang

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; XUEZHIKANG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; DYSLIPIDEMIA; FEMALE; HUMAN; INFLAMMATION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 84873479302     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.90     Document Type: Article

References (24)

1. Li J-J. Inflammation: An important mechanism for different clinical entities of coronary artery disease. Chin. Med. J. 118, 1817-1826 (2005
2. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010
3. Libby P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002
4. Rosenson RS, Tangney CC. Anti-Atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279, 1643-1650 (1998
5. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-Controlled trial. Lancet 360, 7-22 (2002
7. Stettergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur. Heart J. 29, 1753-1760 (2008
8. Al-Shaer MH, Choueiri NE, Suleiman ES. The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis. 3, 22-27 (2004
9. Liu P-Y, Liu Y-W, Lin L-J, Chen J-H, Liao JK. Evidence for statin pleiotropic in humans: Differential effects of statins and ezetimibe on Rho-Associated coiled-Coil containing protein kinase activity, endothelial function and inflammation. Circulation 119, 131-138 (2009
10. Araujo DB, Bertolami MC, Ferreira WP et al. Pleiotropic effects with equivalent low-Density lipoprotein cholesterol reduction: Comparative study between simvastatin and simvastatin/ ezetimibe coadministration. J. Cardiovasc. Pharmacol. 55, 1-5 (2010
11. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravasattin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30, 230-235 (2007
12. Kater AA, Batista MC, Ferreira RG. Synergistic effects of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-Diabetic subjects. Diabet. Metabol. Syndrome 2, 34-41 (2010
13. Lu Z-L, Kou W-R, Du B-M et al. Effects of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am. J. Cardiol. 101, 1689-1693 (2008
14. Li J-J, Lu Z-L, Kou W-R et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from China Coronary Secondary Prevention Study (CCSPS). J. Clin. Pharmacol. 49, 947-956 (2009
15. Li J-J, Hu S-S, Fang C-H et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and Creactive protein: A short-Term time course study in patients with stable angina. Clin. Chim. Acta 352, 217-224 (2005
16. Li J-J, Wang Y, Nie S-P, Li Y-S, Huang Y, Hui R-T. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feeling in patients with cardiac syndrome X. Int. J. Cardiol. 122, 82-84 (2007
17. Li J-J, Fang C-H. Effects of 4 weeks of atorvastatin administration on the anti-inflammatory cytokine interleukin-10 in patients with unstable angina. Clin. Chem. 51, 1735-1738 (2005
18. Zhao S-P, Liu L, Cheng Y-C et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 110, 915-920 (2004
19. Becker, DJ, Gordon RY, Halbert S C et al. Red yeast rice for dyslipidemia in statin-intolerant patients. Ann. Intern. Med. 150, 830-839 (2009
20. Halbert, SC, French B, Gordon R Y et al. Tolerability of red yeast rice (2400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am. J. Cardiol. 105, 198-204 (2010
21. Ridler PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N. Engl. J. Med. 359, 2195-2207 (2008
22. Sabat R, Grutz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 21, 331-344 (2010
23. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104, 746-749 (2001
24. Li J-J, Fang C-H, Li Y-S et al. Effects of simvastatin on anti-inflammatory cytokine IL10 in patients with unstable angina within two weeks. Heart 92, 529-530 (2006